{"text_format":"3","workbook":"xls","n_sheets":1,"sheets":["Sheet0"],"not_rendered":{"external_links":1},"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"Sheet0","index":0,"n_rows":273,"n_cols":10,"rows_kept":273,"flags":["formulas_cached_only"]}
[{"$nulls":4},"Activation Z-Score"]
[]
["Canonical Pathways","Paclitaxel","Nocodazole","Methotrexate","Fluorouracil","Etoposide","Doxorubicin","Cyclophosphamide","Cisplatin","Arabinosylcytosine"]
["Oxidative Phosphorylation",1.029,-4.964,-7.141,5.145,5.485,2.828,-0.593,1.213,-5.925]
["Synaptogenesis Signaling Pathway",-2.722,1.131,-4.964,6.786,4.542,2.959,-1.342,3.888,-3.355]
["EIF2 Signaling",-1.414,-2.692,-6.306,5.082,5.815,2.832,0.243,1.461,-3.845]
["Estrogen Receptor Signaling",0,2.023,-4.341,6.277,5.939,4.808,0.405,3.452,-2.1]
["Cardiac Hypertrophy Signaling (Enhanced)",0.649,2.287,-2.117,8.379,5.048,2.846,1,3.395,-1.512]
["Insulin Secretion Signaling Pathway",0.343,1.18,-4.226,6.068,5.689,4.964,-0.156,1.976,-2.596]
["Ephrin Receptor Signaling",-0.73,1.461,-4.426,5.925,3.8,1.633,-2.117,2.982,-3.138]
["Superpathway of Inositol Phosphate Compounds",-0.277,0.784,-3.4,6.245,3.962,3.838,0.853,3.3,-3.411]
["RAC Signaling",-2.236,-0.626,-4,6,3.153,2.183,-2.558,1.069,-3.441]
["Coronavirus Pathogenesis Pathway",0.457,2.722,4.715,-3.286,-4.25,-1.298,1.134,-3.795,3.479]
["NGF Signaling",-1.5,2.065,-3.606,5.488,3.638,2.524,-0.728,2.309,-2.324]
["3-phosphoinositide Biosynthesis",-0.905,0.626,-3.411,5.568,3.71,3.3,0.229,2.84,-3.578]
["Cardiac Hypertrophy Signaling",-1.414,1.134,-2.065,6.505,4.379,3.272,1.095,2.711,-1.528]
["Signaling by Rho Family GTPases",-1.671,0.822,-3.8,6.788,3.78,2.785,-1.521,1.147,-1.46]
["3-phosphoinositide Degradation",-0.632,0.626,-3.411,5.477,3.441,3.3,0,3.3,-3.411]
["D-myo-inositol-5-phosphate Metabolism",0,0.853,-3.128,5.385,3.578,3.3,0.471,3,-3.71]
["Integrin Signaling",-0.845,1.718,-3.528,6.147,3.43,2.263,-0.617,3.138,-1.616]
["MSP-RON Signaling In Cancer Cells Pathway",-1.512,2.043,-3.13,4.964,3.78,2.132,-0.378,2.837,-2.2]
["Actin Cytoskeleton Signaling",-0.707,1.677,-3.528,5.741,3.182,1.732,-1,2.117,-2.6]
["Adrenomedullin signaling pathway",-1.091,1.569,-2.673,6.083,2.828,3.4,1.091,1.789,-1.706]
["PI3K Signaling in B Lymphocytes",-1,1.606,-2.496,4.6,3.606,2.324,1.5,3.207,-1.886]
["D-myo-inositol (1,4,5,6)-Tetrakisphosphate Biosynthesis",-0.632,0.447,-3.273,4.899,3.3,3,0,2.84,-3.578]
["D-myo-inositol (3,4,5,6)-tetrakisphosphate Biosynthesis",-0.632,0.447,-3.273,4.899,3.3,3,0,2.84,-3.578]
["NRF2-mediated Oxidative Stress Response",0.655,2.744,-1.886,3.138,4.2,2.309,-1,2.828,-3.13]
["Cell Cycle Control of Chromosomal Replication",-0.707,-2.887,-3.357,2.121,3,3.742,0.302,2.714,-2.53]
["Endothelin-1 Signaling",0.655,1.964,-2.496,4.041,3.742,2.668,1.069,2.53,-2.138]
["Superpathway of Cholesterol Biosynthesis",2,2.828,2.646,3.317,2,3.162,2.333,1.897,-1]
["Melanocyte Development and Pigmentation Signaling",-1.069,1.387,-3.051,4.707,3.464,2.309,-0.577,2.53,-1.941]
["Renin-Angiotensin Signaling",-2.138,1.5,-2.53,4.899,2.828,2.324,-0.277,2.111,-2.324]
["Cholecystokinin/Gastrin-mediated Signaling",-1.698,1.606,-3,4.491,2.828,1.807,1.387,1.667,-2.309]
["ERBB Signaling",-2.183,0.688,-3.464,4.899,3.317,1.155,-0.258,1.897,-2.84]
["fMLP Signaling in Neutrophils",-0.894,0.209,-3.3,4.914,2.309,2.309,-1.706,2.673,-2.357]
["14-3-3-mediated Signaling",-1.789,2.558,-2.496,4.6,2.324,1.155,0.894,2.53,-2.138]
["Role of NFAT in Cardiac Hypertrophy",-1.091,2.041,-1.5,5.578,3.051,1.606,1.147,2.065,-2.4]
["P2Y Purigenic Receptor Signaling Pathway",-1.147,1.213,-1.387,5.014,3.606,2,0.943,3.357,-1.698]
["Senescence Pathway",-1.414,0.169,-2.828,5.582,2.667,2.137,1.257,2.414,-1.859]
["Thrombin Signaling",-0.426,2.041,-3.207,5.06,3.606,2.132,1.147,1.291,-1.414]
["HGF Signaling",-2.065,0.218,-3.742,4.811,3.153,1,0,2.309,-3]
["IL-8 Signaling",0,1.48,-2.837,5.425,4.583,2.449,0,2.357,-1.043]
["GNRH Signaling",-0.688,2.065,-2.324,4.243,4,2.4,-0.728,1.147,-2.524]
["Colorectal Cancer Metastasis Signaling",-1.095,1.3,-1.886,4.529,3.8,2.117,0.73,3.8,-0.853]
["Xenobiotic Metabolism General Signaling Pathway",-1.414,1.8,-2.673,4.6,3.638,1.069,0.775,1,-3.13]
["Paxillin Signaling",-1.387,2,-2.714,4.6,2.84,1.604,-1.387,0.905,-2.496]
["ERK5 Signaling",-1.941,1.941,-3.207,3.838,2.5,1.265,-0.277,3.051,-1.732]
["PAK Signaling",-1.807,0.728,-2.53,4.146,2.714,1.387,-1.941,1.508,-2.887]
["Regulation of Actin-based Motility by Rho",-1.698,0.447,-3,3.674,3.545,1.698,-1.46,1.897,-2.138]
["Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes",-0.853,0.392,-3.838,4.899,2.982,0.905,-0.816,2.496,-2.357]
["Regulation Of The Epithelial Mesenchymal Transition By Growth Factors Pathway",-0.209,2.6,-1.732,4.938,4.082,2.065,0.209,1.5,-2.183]
["tRNA Charging",1.342,0,-2.828,3.742,2.714,2.333,-2.236,1,-3.317]
["LPS-stimulated MAPK Signaling",-1.941,0.535,-2.828,4.146,3,2.333,0,2.53,-2.111]
["Apelin Endothelial Signaling Pathway",-1.5,1.091,-2.714,4.596,3.317,2,1.606,2.496,0]
["ERB2-ERBB3 Signaling",-1.897,0.577,-2.828,4,2.53,0,-1.155,3,-3.317]
["CXCR4 Signaling",-1.091,2.294,-2.5,4.352,4.359,1.706,0.6,1.387,-0.943]
["Spliceosomal Cycle",1.633,-0.707,-3.873,3.873,2.138,3.742,-1.069,0.333,-1.732]
["Neurotrophin/TRK Signaling",-1.941,0.302,-3.162,3.9,3,1.941,0,2.121,-2.714]
["RHOGDI Signaling",0.626,-1.4,3.13,-4.116,-2.646,-2.324,1.732,-1.807,1.213]
["Opioid Signaling Pathway",-1.732,-0.174,-3.138,3.592,3.157,1.8,-1.029,2.414,-1.915]
["Glioma Signaling",-1,1.342,-3.162,4.472,3,0.632,1.387,1.633,-2.309]
["HMGB1 Signaling",-1.147,0.728,-2.111,4.811,3.873,1.604,0.943,2.309,-1.291]
["Hepatic Fibrosis Signaling Pathway",0.146,1.021,-2.121,7.034,4.025,2,0.438,1.521,-0.507]
["Salvage Pathways of Pyrimidine Ribonucleotides",-0.302,0,-2.714,4.243,3.606,2.236,-0.535,2.121,-3.051]
["IL-3 Signaling",-2.324,1.213,-2.828,4.243,2.714,-0.333,0,2.646,-2.496]
["PTEN Signaling",0.447,-0.853,3,-4.459,-2.837,-1.279,1.414,-1.5,2.982]
["Acute Myeloid Leukemia Signaling",-2.111,0.535,-2.828,4.583,2.714,0.905,-0.775,2.309,-1.941]
["FLT3 Signaling in Hematopoietic Progenitor Cells",-1.604,1.807,-2.53,4.146,2.887,0.302,-1.387,1.897,-2.138]
["Reelin Signaling in Neurons",-1,1.043,-2.84,5.578,1.941,0.632,-2.236,0.905,-2.5]
["GDNF Family Ligand-Receptor Interactions",-1.941,0.258,-3.162,4.025,2.333,1.897,-0.277,2.449,-2.333]
["Prolactin Signaling",-2.138,0.5,-3.317,3.441,3,1.265,0.535,1.89,-2.53]
["Actin Nucleation by ARP-WASP Complex",-1.698,0,-3.464,3.9,1.807,1.265,-1.698,1.89,-2.887]
["Xenobiotic Metabolism CAR Signaling Pathway",1.043,0,-3.3,3.889,3.153,2.828,1.069,1.069,-2.236]
["IL-15 Production",-0.905,0,-2.828,4.69,4,2.53,0,2.496,-1.134]
["Gαq Signaling",0,0.853,-1.508,4.95,3.207,2.668,2.236,2.887,0]
["ERBB4 Signaling",-1.508,1.604,-2.646,4,2.449,0.707,0.333,2,-3]
["G Beta Gamma Signaling",0,2.065,-2.673,4.243,3.207,1.213,-0.258,2.714,-1.807]
["VEGF Signaling",-0.471,2.683,-1.508,5,3.207,0.577,1.069,2.111,-1.508]
["Coronavirus Replication Pathway",1.342,0,-3.207,2.5,2.714,2.53,2.668,-1,-2.121]
["Necroptosis Signaling Pathway",2.132,-0.378,-4.536,4.315,2.921,0.655,0,0.243,-2.858]
["Renal Cell Carcinoma Signaling",-1.941,0.577,-3,4.123,2.828,0.905,-0.277,2.236,-2.111]
["Agrin Interactions at Neuromuscular Junction",-1.897,2.111,-2.53,3.162,2.887,0.378,-1.387,2.121,-1.508]
["BER (Base Excision Repair) Pathway",-1.414,-1.897,-3.317,2.111,2.646,1.134,0,2.53,-2.828]
["Thrombopoietin Signaling",-1.604,0.775,-3,4.123,2.828,0.707,0.277,2,-2.53]
["Pyridoxal 5'-phosphate Salvage Pathway",-0.378,1.155,-2.333,4.123,3.317,1.5,0.577,1.89,-2.53]
["Neuregulin Signaling",-1.213,1.043,-2.5,4.583,3.153,0.632,0.229,1.897,-2.5]
["Corticotropin Releasing Hormone Signaling",-0.277,1.387,-1.897,3.771,2.887,2.714,1.155,2.53,-1.069]
["CNTF Signaling",-1.732,0.905,-2.449,4.472,3,0.378,-0.905,1.633,-2.121]
["IL-6 Signaling",-1.147,2.357,-1.732,4.707,2.673,0.535,0.943,2.324,-1.069]
["Remodeling of Epithelial Adherens Junctions",-0.333,0.905,-2.53,3,1.897,1.134,-2.887,2.449,-2.333]
["BMP signaling pathway",-1.155,0.632,-1.633,3.5,3,2.53,-0.378,2.714,-1.897]
["Natural Killer Cell Signaling",-0.408,1.4,-2.668,4.323,2.236,1.528,-1.46,1.279,-2.132]
["PDGF Signaling",-1,0,-2.887,4.899,2.714,1.155,0.5,2.121,-2.138]
["VEGF Family Ligand-Receptor Interactions",-1.069,1.698,-2.121,4.243,2.828,0.333,0.905,2.449,-1.732]
["Dopamine-DARPP32 Feedback in cAMP Signaling",-0.258,0.5,-1.091,3.78,3.3,1.886,1.414,3.207,-1.877]
["Leukocyte Extravasation Signaling",0,0.784,-2.982,4.382,4.025,2.065,-0.626,1,-1.414]
["RANK Signaling in Osteoclasts",-2.121,-0.302,-2,4.472,2.236,1.667,1.897,1.667,-0.905]
["CSDE1 Signaling Pathway",-2.887,0,-1.941,2.183,3.9,2.183,0.243,2.138,-1.789]
["IGF-1 Signaling",-2.5,0,-3.051,3.838,3.357,0.775,0,2.138,-1.604]
["Acute Phase Response Signaling",-0.943,2.236,-2.138,4.158,3.051,0.5,1.342,1.091,-1.789]
["Estrogen-Dependent Breast Cancer Signaling",-1.732,-0.333,-2.646,3.207,3.317,1,0.577,2.828,-1.508]
["Unfolded protein response",2.673,3.441,-0.577,2.84,3.5,1.89,1.291,0.655,-0.243]
["Apelin Cardiomyocyte Signaling Pathway",0.277,1.5,-1.134,4.359,3.606,2.496,1.604,0.707,-1.414]
["TCA Cycle II (Eukaryotic)",0.707,-1.897,-3.464,3,0.447,1.342,-1.342,2.236,-2.646]
["GM-CSF Signaling",-1.155,1.291,-3,4.359,2.828,-0.333,-0.577,1.414,-2.111]
["RHOA Signaling",-0.943,0.6,-2.837,3.889,3.838,1.698,-1.225,0.535,-1.5]
["Oncostatin M Signaling",-1,1.414,-2.236,3,2.449,-0.447,-1.633,2.236,-2.646]
["FGF Signaling",-0.905,0.333,-3,4.264,3.317,1,0.577,1.134,-2.53]
["Antioxidant Action of Vitamin C",-2.111,-1.89,0.447,-3,-2.236,-2.449,-2,-1.89,1]
["RAN Signaling","N/A",-1.633,-2.646,3.464,2.646,1.89,-2.828,"N/A",-1.89]
["NF-κB Activation by Viruses",-2.309,0.277,-2.449,4.472,2.121,-0.378,0.302,2.646,-1.941]
["Pyrimidine Deoxyribonucleotides De Novo Biosynthesis I",-1.633,-2.828,-2.646,2,2.646,1.342,-1.342,"N/A",-2.449]
["CCR3 Signaling in Eosinophils",-1.265,1.155,-2.828,3.873,2.646,0.816,-0.302,1.342,-2.53]
["ILK Signaling",-1.095,0.493,-2.041,3.857,3.333,1.671,1.897,1.961,-0.392]
["Glioblastoma Multiforme Signaling",-1.134,0.392,-2.683,4.243,3.9,0.447,0.577,1.291,-2.065]
["Role of NANOG in Mammalian Embryonic Stem Cell Pluripotency",-1.508,0.905,-1.89,3.638,2.828,-0.302,-0.632,2.449,-2.53]
["GP6 Signaling Pathway",0.258,2,-1.633,4.359,2.828,1.155,1.667,1.134,-1.508]
["Endocannabinoid Developing Neuron Pathway",-0.775,0.728,-2.309,3.138,3.873,0.277,-2.183,0.905,-2.324]
["White Adipose Tissue Browning Pathway",0.302,1.265,-1.667,3.5,3.5,2.714,-0.707,1.732,-1.069]
["Thyroid Cancer Signaling",-2.309,-0.258,-2.53,3,2.333,0.905,0.775,2.646,-1.604]
["TNFR1 Signaling",-0.816,0.447,-2.236,3.464,3,2.53,1.134,2.121,-0.447]
["Gα12/13 Signaling",-1.732,0.5,-1.155,4.2,3.051,1.807,-0.5,1.807,-1.387]
["Autophagy",-0.392,1.372,-1.569,4.082,1.569,4.116,0.18,1.677,-1.095]
["α-Adrenergic Signaling",-0.302,0.535,-2.887,3.742,2.121,2.333,0,2.449,-1.667]
["Fc Epsilon RI Signaling",-1.732,2,-2.333,3.273,3,0.302,0,0.378,-2.887]
["PEDF Signaling",-2.53,1.155,-1.633,3.13,2.121,0.707,0,2.53,-1.897]
["p38 MAPK Signaling",-0.632,1.604,-1.134,2.982,3.742,1.633,-0.302,1.732,-1.897]
["Mouse Embryonic Stem Cell Pluripotency",-0.243,1.291,-2.333,3.545,3.606,0,-0.535,1.941,-2.138]
["Glycolysis I",0,-0.333,-2.53,2.333,2.714,2.646,3.606,"N/A",1.414]
["ERK/MAPK Signaling",-1.461,1.219,-0.73,3.244,3.182,0.928,-1.616,2.117,-1.029]
["Ceramide Signaling",-1.069,0,-3.162,2.294,1.941,2.111,0,2.111,-2.828]
["IL-2 Signaling",-1.897,0.905,-2.449,3.742,2.236,0,0.333,2,-1.897]
["Erythropoietin Signaling Pathway",-2.683,0.218,-3,3.536,2.673,1,-0.447,0.258,-1.606]
["STAT3 Pathway",0.535,1.155,-1.897,3.578,3.464,0.816,-0.333,1.667,-1.897]
["Non-Small Cell Lung Cancer Signaling",-1.265,0.632,-2.449,3.5,2.121,0,-0.577,2.449,-2.333]
["Macropinocytosis Signaling",-0.632,1.265,-2.646,3.317,2.828,1,-1,"N/A",-2.449]
["Superpathway of Methionine Degradation",-0.447,-1.89,-3,1.633,0.378,2.53,-1.89,0.447,-2.646]
["Relaxin Signaling",-0.905,0.905,0.816,4.025,2.53,1.732,0.905,2.111,0.905]
["UVB-Induced MAPK Signaling",-2.121,-0.302,-2,3.606,2.449,1,1.667,-0.447,-1.134]
["Ovarian Cancer Signaling",-0.5,1.155,-1.667,4.243,3,0.707,0,2.53,-0.905]
["IL-1 Signaling",-0.816,0.816,-1,3.464,2.236,2.828,1.633,1.897,0]
["Assembly of RNA Polymerase II Complex",0.707,0,-3.357,3.638,2.111,2.333,-0.632,"N/A",-1.89]
["UVC-Induced MAPK Signaling",-1.265,0.905,-2.236,2.828,2.449,1.342,0.378,1,-2.121]
["PPAR Signaling",0.943,-1.698,1.508,-2.711,-1.667,-2.5,-0.535,-2.121,0.832]
["SPINK1 General Cancer Pathway",-1,0.707,-2,3.606,2.121,-0.816,-0.333,2,-1.89]
["Production of Nitric Oxide and Reactive Oxygen Species in Macrophages",-0.209,2.117,0.688,3.28,3.138,0.853,2.646,-0.243,1.225]
["EGF Signaling",-2.111,0,-2.449,4,3.162,0.333,0.277,-0.447,-1.508]
["Synaptic Long Term Potentiation",0,1.147,-0.943,2.985,3,1.604,0.5,2.496,-1.606]
["NAD Signaling Pathway",-0.816,-0.426,-2.673,2.041,2.5,1.279,-0.655,2.041,-1.789]
["JAK/STAT Signaling",-1.604,0.832,-3,2.785,2.309,0,0.258,1.667,-1.732]
["Xenobiotic Metabolism PXR Signaling Pathway",0.894,0.209,-2.065,3.157,1.279,2.065,-0.258,1.5,-2.524]
["Endometrial Cancer Signaling",-2.111,-0.535,-1.667,3,1.667,0.333,0,1.667,-2.887]
["Growth Hormone Signaling",-1.667,-0.302,-2.449,3,2.449,1.633,0.905,-1,0.447]
["Aldosterone Signaling in Epithelial Cells",0,0.577,-2.121,3.357,1.633,2.449,1.414,"N/A",-2.236]
["TGF-β Signaling",-0.832,0.535,-2.646,2.982,2.714,1,-0.707,0.707,-1.508]
["HER-2 Signaling in Breast Cancer",-1.976,0.649,-1.061,4.202,2.214,1.616,-0.137,1.061,-0.686]
["Estrogen-mediated S-phase Entry","N/A",-1.342,-2.121,1.342,2.121,1.342,-0.378,2.236,-2.646]
["Pancreatic Adenocarcinoma Signaling",0.218,1.606,-0.277,3.674,1.886,1.5,-0.728,2.5,-1.069]
["Bladder Cancer Signaling",-0.378,-0.378,-2.449,2.449,2,"N/A",-0.816,2.236,-2.646]
["Melatonin Signaling",0.333,0.302,-1.414,2.714,2,2.646,1.414,1.667,-0.816]
["Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza",-3,-0.707,-1.342,2.449,0.333,0,-1,2.496,-1.897]
["Angiopoietin Signaling",-1.667,0.707,-1.89,2.673,0.816,0.905,-0.707,2.111,-1.667]
["Superpathway of Geranylgeranyldiphosphate Biosynthesis I (via Mevalonate)","N/A",2,2.236,2,"N/A",2.646,2,2.236,"N/A"]
["HIPPO signaling",1.265,-0.632,2.714,-2.236,-0.333,-0.378,-1,-2.646,1.897]
["Death Receptor Signaling",0,1.155,-0.707,3.838,1.291,2.138,1.414,1.604,-0.816]
["Gαs Signaling",0,1.342,-0.816,3.051,2.449,2.333,-0.447,2.121,-0.378]
["Melanoma Signaling",-0.905,0.333,-2.121,2.84,1.667,-1,0,1.89,-2.111]
["Role of MAPK Signaling in Promoting the Pathogenesis of Influenza",0.277,1.5,-1.134,3.153,1.732,3.357,-0.832,0.302,-0.577]
["Pyrimidine Ribonucleotides De Novo Biosynthesis",-1,-1,-2.646,2.121,2.449,0.816,-1.134,0.333,-1.342]
["Amyotrophic Lateral Sclerosis Signaling",-0.277,1.508,-1.667,2.558,1.508,1.897,-1.508,1.155,-0.707]
["CDK5 Signaling",0.535,1.147,-0.243,3.128,2,2,-0.258,2.673,-0.688]
["Aryl Hydrocarbon Receptor Signaling",-1.291,-1.606,-0.894,1.134,1.606,-0.229,1.342,2.828,-1.698]
["HOTAIR Regulatory Pathway",0.258,0,-2.183,2.746,2.041,1.528,-0.229,1.387,-2.138]
["UVA-Induced MAPK Signaling",0,1.414,-1.342,3.606,2.236,1.342,0.333,"N/A",-2.236]
["Gluconeogenesis I",0,-0.707,-2.53,1.89,2.121,2,2.53,"N/A",0.707]
["WNT/Ca+ pathway",1.633,"N/A",-1,2.714,2,1.89,"N/A",1.897,-1.342]
["Purine Nucleotides De Novo Biosynthesis II","N/A",-2,-2.236,2.236,"N/A",1,-1,2,-2]
["ATM Signaling",0.577,1.155,1.069,-1.279,0.229,2.357,1.732,-2,2]
["Insulin Receptor Signaling",-1.213,0.626,-3.578,2.556,0.943,0.447,0,0.5,-2.524]
["Nitric Oxide Signaling in the Cardiovascular System",-0.775,0.688,-1,2.828,2.333,1.265,1.387,1.732,0.333]
["Tumor Microenvironment Pathway",-0.209,0.626,-2.309,3.528,2.828,0.577,-0.218,1.886,0]
["Sphingosine-1-phosphate Signaling",0,1.941,-1.89,2.858,1.897,1.069,1.604,-0.447,-0.378]
["IL-7 Signaling Pathway",-1,0.535,-1.134,2.887,2.324,0,0.258,1.897,-1.897]
["Mitotic Roles of Polo-Like Kinase",-0.447,-1.342,-2,2.236,0,1.897,-0.447,1.633,-1.897]
["Apelin Adipocyte Signaling Pathway",1.897,0.577,-2.236,0.905,2.333,0.632,1.414,-0.707,-1.134]
["PFKFB4 Signaling Pathway",-0.707,1.414,-0.333,1.265,2.121,1.414,-1.414,1.667,-1.414]
["Xenobiotic Metabolism AHR Signaling Pathway",0.905,0.277,-1.155,2.5,2.111,1.342,0.707,0.577,-2.138]
["Glioma Invasiveness Signaling",-1.387,-0.333,-2,2.84,2.236,0.333,0.302,1.134,-1.134]
["Role of IL-17F in Allergic Inflammatory Airway Diseases",-0.816,0,-2.236,2.53,"N/A",2.236,"N/A",2.236,-1.633]
["Androgen Signaling",-2.121,0.302,-1.414,1.897,1,1.89,1.265,1.667,0]
["Cardiac β-adrenergic Signaling",1.265,1.604,2.324,0.655,1.155,0.258,0.577,1.387,2.324]
["mTOR Signaling",-0.209,1.3,-1.698,2.466,3.153,0.447,1.225,-0.775,0.243]
["NER (Nucleotide Excision Repair, Enhanced Pathway)",0.258,0,-2.556,2.041,2.558,2.496,-0.209,1.155,0.229]
["Kinetochore Metaphase Signaling Pathway",-0.832,-0.243,-0.229,-1.291,3.128,1.961,1.291,1.789,-0.6]
["MYC Mediated Apoptosis Signaling",0.333,1.667,-1.134,1.291,1.732,2.333,0,1.508,-1.342]
["Retinoic acid Mediated Apoptosis Signaling",-0.447,0.816,-2,2.236,1.414,0.707,"N/A",1.633,-2]
["Pyrimidine Ribonucleotides Interconversion","N/A",-0.707,-2.449,2.121,2.236,0.816,-1.134,0.378,-1.342]
["Role of CHK Proteins in Cell Cycle Checkpoint Control",-1,-1.633,-1.667,2.324,0.707,1.732,0,1.414,-0.632]
["Pentose Phosphate Pathway","N/A",1.633,-1,2,2.236,"N/A",-2,"N/A",-2.236]
["Induction of Apoptosis by HIV1",1.265,1.667,-0.816,2.828,0.632,3.162,0,0.632,0]
["FAT10 Cancer Signaling Pathway",0.707,1,-0.447,3.5,2.111,-0.378,1,1.134,0.707]
["Chemokine Signaling",-0.832,0.535,-1.897,3,1.897,1,0.535,0.707,-0.577]
["PD-1, PD-L1 cancer immunotherapy pathway",0.302,-0.832,-0.632,-2.683,-2.138,-0.905,-0.832,-1.508,1]
["Cysteine Biosynthesis III (mammalia)","N/A",-1.342,-2.449,1,-0.447,1.633,-1.342,"N/A",-2.449]
["iNOS Signaling",-1.342,0.447,"N/A",3,2.646,"N/A",1.342,1.342,-0.447]
["eNOS Signaling",-1.291,0.471,0,2.711,2.138,0.728,1.5,1.698,0]
["HIF1α Signaling",-0.333,1.093,-0.898,4.23,1.414,0.577,1.768,0.186,0]
["Antiproliferative Role of Somatostatin Receptor 2",0,1.134,-1.134,2.887,1.342,0.447,-0.707,1,-1.633]
["Inhibition of Angiogenesis by TSP1",0,2.236,"N/A",2,2.449,0,2,1,0.447]
["Ephrin B Signaling",0.333,0,-2.111,3.051,1.508,1.667,-0.302,0.378,-0.707]
["Synaptic Long Term Depression",1.147,1.698,-1.291,1.964,1.508,1.155,0,0.707,-0.535]
["Protein Kinase A Signaling",-1.581,1.265,-0.309,2.066,1.48,0.343,0,2.137,-0.762]
["IL-17A Signaling in Airway Cells",-1.134,0.378,"N/A",3.5,1.89,0.707,0.378,1.134,-0.816]
["PI3K/AKT Signaling",-0.577,1.3,-2.2,2.064,1.89,-0.408,0.186,0.853,-0.392]
["CD40 Signaling",-1.134,-0.816,"N/A",3.9,1,1.89,0.707,-0.378,0]
["Methionine Degradation I (to Homocysteine)","N/A",-1,-2.236,1,-1,1.342,-1,"N/A",-2.236]
["Epithelial Adherens Junction Signaling",-0.686,1.257,-1.414,1.982,0.365,1.89,-2.197,0,0]
["CD27 Signaling in Lymphocytes",0.447,-0.816,1,2.673,-2,1.134,"N/A",-0.378,1.342]
["Huntington's Disease Signaling",-0.229,0.626,-1.5,2.646,1.964,-0.209,1.147,-1.155,-0.277]
["Hypoxia Signaling in the Cardiovascular System",-0.302,0.816,-1,1.265,3.162,0,1.414,1.134,-0.378]
["Telomerase Signaling",-0.775,0.688,-1.604,1.8,2.496,0,-0.243,0.905,-0.943]
["Notch Signaling",1.342,2.236,"N/A",0.378,2.236,"N/A",2.236,1,"N/A"]
["MSP-RON Signaling In Macrophages Pathway",-1.155,0.333,-1.134,1.606,2.53,0,0.302,0.707,-1.508]
["p70S6K Signaling",0,0.626,-1.606,2.828,2.138,0.5,0.218,0.632,-0.688]
["Tryptophan Degradation III (Eukaryotic)",-1,2,"N/A",2,2,1.633,0.447,"N/A","N/A"]
["Small Cell Lung Cancer Signaling",0,-1,0,2.828,1.897,0.707,-0.632,1.414,-0.378]
["Role of RIG1-like Receptors in Antiviral Innate Immunity","N/A","N/A","N/A",2,2,2,"N/A",2.828,"N/A"]
["Role of PI3K/AKT Signaling in the Pathogenesis of Influenza",-0.707,0,-1,2.887,1,1.134,0.378,1.633,0]
["Osteoarthritis Pathway",-0.688,2.138,0.277,2.268,1.528,0.5,-0.832,0.447,0]
["Colanic Acid Building Blocks Biosynthesis",0.447,1,"N/A",2.646,"N/A",2.236,"N/A",2.236,"N/A"]
["TWEAK Signaling",-0.447,"N/A",-1,2.121,1.342,2,"N/A",1.633,"N/A"]
["Leptin Signaling in Obesity",-1.342,0.816,-1,3.162,"N/A",0.378,0.816,"N/A",-1]
["Inhibition of ARE-Mediated mRNA Degradation Pathway",-0.943,2.065,0.426,-0.169,0,-1.177,1.606,0.426,1.569]
["Sirtuin Signaling Pathway",-0.7,1.692,1.089,-0.62,-0.674,1.622,-0.361,1.265,-0.295]
["AMPK Signaling",0,1.225,-1.043,0.603,1.279,0.816,0.6,1.225,1.46]
["Regulation of eIF4 and p70S6K Signaling",-1.5,0.471,-1.155,2.2,1.508,-0.577,-0.258,0,-0.5]
["Regulation of Cellular Mechanics by Calpain Protease",-0.905,0,-1.667,2.53,1,0.816,-0.333,-0.333,-0.577]
["Toll-like Receptor Signaling","N/A",0,"N/A",2.333,1,1,2,0,-1.633]
["Cell Cycle: G2/M DNA Damage Checkpoint Regulation",0.577,1.897,0.378,0.258,-0.577,-1.5,1,0.632,1.069]
["Activation of IRF by Cytosolic Pattern Recognition Receptors",-1,0.333,-0.447,0.707,1,1.633,0,2.714,0]
["Granzyme B Signaling",-1,"N/A",-1.342,"N/A",2.449,1,2,"N/A","N/A"]
["PPARα/RXRα Activation",0.688,-0.426,1.941,-1.667,-0.277,-1.279,0,0,1.5]
["BAG2 Signaling Pathway",2.309,2.309,0.905,-0.243,-0.333,0.258,-0.832,-0.577,0]
["Semaphorin Neuronal Repulsive Signaling Pathway",1.291,0.447,-0.632,-1.029,1.606,-0.229,-1.606,-0.535,-0.258]
["Ferroptosis Signaling Pathway",1.183,1.567,-0.522,2.214,0,1.095,-0.18,0.2,-0.557]
["Endoplasmic Reticulum Stress Pathway",0.816,0.816,-0.447,1.342,2.646,"N/A",-0.816,0,-0.447]
["Fatty Acid β-oxidation I","N/A","N/A","N/A","N/A",2,1.89,1,"N/A",-2.236]
["Lymphotoxin β Receptor Signaling",-0.447,0.378,"N/A",2.111,1.633,0.816,0.378,"N/A",-1.342]
["Vitamin-C Transport","N/A","N/A",-1,1.342,2,"N/A",-1.342,"N/A",-1.342]
["BEX2 Signaling Pathway",1.069,1.414,0,0.218,1.698,-0.832,-0.728,0.5,0.258]
["Role of PKR in Interferon Induction and Antiviral Response",-1.964,-0.229,0,1.633,1.279,0.218,0.229,0.894,-0.243]
["Cyclins and Cell Cycle Regulation",0.378,-1,0,-0.894,1,-0.632,-1,0.905,-0.832]
["p53 Signaling",0.258,1.069,0.378,-0.426,-1,0.832,-1.387,0.632,0.632]
["Role of BRCA1 in DNA Damage Response",-1,"N/A",-0.447,1,1.414,1.732,"N/A",-1,0]
["Mevalonate Pathway I","N/A","N/A",2,"N/A","N/A",2.449,"N/A",2,"N/A"]
["Cholesterol Biosynthesis III (via Desmosterol)","N/A",2,"N/A",2.646,"N/A","N/A",1.342,0.447,"N/A"]
["Cholesterol Biosynthesis I","N/A",2,"N/A",2.646,"N/A","N/A",1.342,0.447,"N/A"]
["Cholesterol Biosynthesis II (via 24,25-dihydrolanosterol)","N/A",2,"N/A",2.646,"N/A","N/A",1.342,0.447,"N/A"]
["Sumoylation Pathway",0.577,-0.728,0.447,-1.4,-2.065,0.243,-0.229,-0.333,-0.258]
["Endocannabinoid Cancer Inhibition Pathway",0.471,-0.218,0.471,-2.043,-0.218,-0.229,-0.229,-1.706,0.655]
["IL-23 Signaling Pathway","N/A",0.447,"N/A",3.207,1.342,0.378,0.378,0.447,"N/A"]
["Apoptosis Signaling",0.258,0.5,0.258,0.557,1.698,1.5,0.5,-0.229,0.577]
["Amyloid Processing",-1,-0.378,-1,1,1.342,0,-0.447,-0.447,-0.447]
["Dilated Cardiomyopathy Signaling Pathway",-0.302,0.258,1,0.688,-0.243,0.775,-1.941,0.5,0.302]
["4-1BB Signaling in T Lymphocytes",0,"N/A","N/A",2.449,"N/A",2,"N/A",1.342,"N/A"]
["Interferon Signaling",-1.89,0.333,"N/A",1,0,0,-1.342,1.134,"N/A"]
["Role of p14/p19ARF in Tumor Suppression",2,"N/A",1,-2.53,"N/A",0,"N/A","N/A","N/A"]
["IL-22 Signaling","N/A",1.342,"N/A","N/A",2.646,"N/A",0.447,"N/A",-1]
["FAT10 Signaling Pathway","N/A",0,0,0.816,1.633,1.633,"N/A",1.342,0]
["Cell Cycle: G1/S Checkpoint Regulation",0,-0.632,0.535,-1,-0.535,-0.905,-0.302,-0.905,0.577]
["Glutathione Redox Reactions I",1.633,1.134,"N/A","N/A",2,"N/A","N/A",0,"N/A"]
["WNT/β-catenin Signaling",0,0.277,0.535,-0.378,1.414,-0.277,0.728,0.5,0.258]
["VDR/RXR Activation",0.447,-1.265,0.447,0.447,0.447,"N/A",-0.447,"N/A",0.816]